Vimarsana
Biggest News Aggregation in the World

Vertex Ventures News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Vertex Ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Vertex Ventures Today - Breaking & Trending Today

Coinbase Wallet Users May Have Earned Crypto During Phasing Continue for Alameda - Vimarsana News

Coinbase Wallet Users May Have Earned Crypto During Phasing Continue for Alameda

Ethereum's transition to proof-of-stake (PoS) is ubtc crypto pricenderway, with the Merge event successfully completing on the testnet Kiln. This marks a significant

India welcomes 2022's 10th unicorn in less than 2 months - Vimarsana News

India welcomes 2022's 10th unicorn in less than 2 months

On Tuesday, the Bengaluru and San Francisco-based startup said it has secured $100 million in a Series C funding round led by Greenoaks. Existing investors Nexus Venture Partners, Lightspeed Venture Partners, and Vertex Ventures also participated in the round.

Brands by scions attract VC money; Ola Electric layoffs - Vimarsana News

Brands by scions attract VC money; Ola Electric layoffs

Happy Monday! A new wave of brands founded by second generation entrepreneurs is snagging venture capital. This and more in todays packed edition of ETtech Morning Dispatch.

Japan's Weakness in Bitcoin Market Continues - 3ajlnews donations crypto - Vimarsana News

Japan's Weakness in Bitcoin Market Continues - 3ajlnews donations crypto

The price of Bitcoin (BTC) has been steadily incresats cryptoasing over the past few days, with a current price of around $41,000. However, the dominance of Bitc

Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio for a potential value of $3 billion - Vimarsana News

Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio for a potential value of $3 billion

Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK)of its portfolio company EyeBio for a potential value of $3 billion This acquisition reflects the significant clinical progress